Welcome to our dedicated page for Generation Bio Co. news (Ticker: GBIO), a resource for investors and traders seeking the latest updates and insights on Generation Bio Co. stock.
Generation Bio Co. (NASDAQ: GBIO) is a clinical-stage biotechnology company advancing nonviral genetic medicines through its proprietary cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms. This page serves as the definitive source for official company announcements, including clinical trial milestones, strategic partnerships, and scientific advancements.
Key Resources: Access real-time updates on GBIO’s progress in developing re-dosable gene therapies for liver diseases, retinal disorders, and autoimmune conditions. Content categories include regulatory filings, research publications, and executive leadership insights. Investors will find earnings reports and corporate governance announcements alongside updates on manufacturing scalability.
Why Bookmark This Page: Stay informed about innovations in nonviral delivery systems designed to overcome immunogenicity challenges. Our curated news collection ensures you never miss critical developments in GBIO’s pipeline or technology enhancements. Check back regularly for verified updates directly from the company and trusted industry sources.
Generation Bio (Nasdaq: GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, Geoff McDonough, M.D., will engage in a fireside chat scheduled for Wednesday, April 9th at 12:45 p.m. ET. Investors and interested parties can access the live webcast through the investor section at investors.generationbio.com, where a replay will remain available for 30 days after the event.
Generation Bio (GBIO) reported its Q4 and full year 2024 financial results, highlighting its focus on developing siRNA therapeutics for T cell-driven autoimmune diseases. The company's T cell-selective lipid nanoparticle (LNP) technology achieved approximately 98% knockdown of B2M protein in human T cells in both in vitro and mouse studies.
Key financial metrics include a cash position of $185.2 million as of December 31, 2024, expected to fund operations into 2H 2027. R&D expenses were $15.5 million for Q4 and $61.3 million for FY2024. The company reported a net loss of $21.4 million ($0.32 per share) for Q4 and $131.7 million ($1.98 per share) for FY2024.
Generation Bio plans to announce its lead target and indication in mid-2025, with an IND application scheduled for second half of 2026.
Generation Bio (Nasdaq: GBIO), a biotechnology company focused on developing treatments for T cell-driven autoimmune diseases, has announced its participation in the upcoming TD Cowen 45th Annual Health Care Conference.
The company's president and CEO, Geoff McDonough, M.D., will deliver a presentation on Monday, March 3, 2025, at 9:10 a.m. ET in Boston. Investors and interested parties can access a live webcast of the presentation through the investor section of Generation Bio's website at investors.generationbio.com. The presentation recording will remain available for replay on the website for 30 days after the event.
Tubulis has appointed Matthew Norkunas, MD, MBA, as Chief Financial Officer and President of Tubulis Inc. Based in the company's Cambridge office, this appointment strengthens their U.S. presence and executive leadership. Dr. Norkunas brings significant experience in biotech financial leadership, having previously served as CFO at Generation Bio (GBIO) and SomaLogic.
His background combines medical expertise as a trained anesthesiologist with extensive financial acumen, including experience in healthcare investment and operational roles. The appointment comes at a important growth stage for Tubulis, which is developing ADC (Antibody-Drug Conjugate) drug candidates. Dr. Norkunas will focus on advancing the company's strategic objectives and positioning it for long-term success in the ADC space.
Generation Bio (NASDAQ:GBIO) announced its strategic focus on developing siRNA therapeutics for T cell-driven autoimmune diseases using their cell-targeted lipid nanoparticle (ctLNP) delivery technology. The company aims to selectively modulate T cells in vivo by silencing hard-to-drug targets.
Recent non-human primate data showed ctLNPs effectively target T cells with strong selectivity for CD8+ and CD4+ effector T cells and NK cells. The company plans to submit its first IND in the second half of 2026 and enter clinical trials within its cash runway, which extends into the second half of 2027.
The company announced organizational changes, including Phillip Samayoa, Ph.D. succeeding Matthew Stanton, Ph.D. as chief scientific officer, and Kevin Conway being elected as chief financial officer. A chief medical officer appointment is expected in 2025.
Generation Bio (GBIO) reported its Q3 2024 financial results and business highlights. The company presented data at ESGCT showing successful selective in vivo delivery of mRNA to T cells in non-human primates using their cell-targeted lipid nanoparticle platform. Financial highlights include a cash position of $199.8 million, expected to fund operations into 2H 2027. Q3 2024 showed reduced losses with net loss of $15.3 million ($0.23 per share) compared to $28.3 million ($0.43 per share) in Q3 2023. R&D expenses decreased to $15.1 million from $21.9 million, and G&A expenses reduced to $9.2 million from $11.6 million year-over-year.
Generation Bio presented new data on its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms at the ESGCT 31st Annual Congress. The company showcased results from a non-human primate study where a single 1 mg/kg dose of ctLNP-mRNA selectively delivered mRNA to a majority of circulating T cells, with balanced distribution to CD4+ and CD8+ cells. This confirms and improves upon previous murine studies.
The biodistribution to other organs and monocytes was minimal, demonstrating high specificity. Generation Bio's Chief Science Officer, Matt Stanton, expressed confidence in pursuing T cell targeted in vivo genetic medicines based on these robust results. Additionally, the company presented updates on iqDNA, focusing on methods to improve protein expression and stability against degradation.
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company focused on developing genetic medicines for rare and prevalent diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. Geoff McDonough, M.D., the company's president and CEO, will engage in a fireside chat on Thursday, September 19, 2024, at 10:20 a.m. ET in New York.
Investors and interested parties can access a live webcast of the presentation through the investor section of Generation Bio's website at investors.generationbio.com. For those unable to attend the live event, a replay will be available on the same platform for 30 days following the conference.
Generation Bio Co. (Nasdaq: GBIO) reported its Q2 2024 financial results, highlighting a cash balance of $216.9 million, expected to fund operations into 2H 2027. The company's focus remains on developing in vivo genetic medicines using its proprietary cell-targeted LNP delivery system. Key financial metrics include:
- R&D expenses: $16.4 million, down from $21.8 million in Q2 2023
- G&A expenses: $9.5 million, decreased from $13.0 million in Q2 2023
- Net loss: $20.4 million ($0.31 per share), improved from $31.1 million ($0.47 per share) in Q2 2023
Generation Bio is advancing therapies for T cells, hematopoietic stem cells, and hepatocytes, aiming to create redosable, point-of-care treatments that are scalable at low cost.
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company focused on developing genetic medicines for rare and prevalent diseases, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's president and CEO, Geoff McDonough, M.D., will engage in a fireside chat on Tuesday, August 13th, 2024, at 2:30 p.m. ET in Boston.
Investors and interested parties can access a live webcast of the presentation through the investor section of Generation Bio's website at investors.generationbio.com. For those unable to attend the live event, a replay will be available on the same platform for 30 days following the conference.
